AstraZeneca has revealed it has expanded membership of its Senior Executive Team, which comes into effect immediately. The new changes include increased representation of the company’s ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Getty Images AstraZeneca chief ... The story of AstraZeneca's adventures in vaccines and politics is impossible to separate from the background of the man in charge. As one of his competitors ...

AstraZeneca and Pfizer have announced a new approach to drug development, through a public-private partnership with the Quebec government. The three partners aim to bridge the gap between early ...

Growing up with more hardships, those from disadvantaged class backgrounds also tend to become skilled at identifying barriers to success. They can see issues coming that may derail a team’s plans.

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

Under the terms of the agreement, AstraZeneca will leverage Immunai ... has quickly become a key player in the biotech space.

AstraZeneca will pay CSPC $100 million upfront, with potential for up to $1.92 billion in milestone payments. Airsupra Phase 3b trial shows significant reduction in severe asthma exacerbations ...

Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Oct 7 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd (1093.HK), opens new tab in an exclusive licence agreement to ...

AstraZeneca said on Monday (Oct 7) it would pay up to US$1.92 billion to CSPC Pharmaceutical Group in an exclusive licence agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.